ReviewIntensive care medicine experimental2025
Haemoadsorption to remove inflammatory mediators in sepsis: past, present, and future.
Review in Intensive care medicine experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- HA-330 hemoadsorption in septic shock requiring high-dose norepinephrine: a multicenter randomized controlled trial (CLEANSE).Critical care (London, England) · 2026Trial
- Hemoadsorptionin Critically Ill Pediatric Oncology and Hemato-Oncology Patients: A Systematic Review with Structured Narrative Synthesis.Children (Basel, Switzerland) · 2026Review
- The role of hemoadsorption in septic shock: toward a personalized approach.Critical care (London, England) · 2026Review
- Effects of hemoadsorption on plasma catecholamine levels: an in vitro study.Scientific reports · 2026Article
- Granulocyte and monocyte adsorption therapy in sepsis: a propensity score-matched analysis.Journal of intensive care · 2026Article
- Clinical practice in using corticosteroids and adjunctive sepsis therapies at the bedside among European ICUs: an ESICM-endorsed survey.Intensive care medicine experimental · 2026Article
- Telodendrimer nanotrap for selective cytokine removal from sepsis patient plasma.Frontiers in immunology · 2026Article
- A robust and scalable immunoadsorbent platform based on the high-affinity M03-IgG antibody for targeted IL-6 Removal in cytokine storm.Frontiers in immunology · 2026Article
- Bridging sepsis physiology and biosensor engineering: a clinical perspective on electrochemical cytokine sensor design.Frontiers in bioengineering and biotechnology · 2026Article
- Knowledge gaps in extracorporeal blood purification: what would be required for its successful application in septic shock?Intensive care medicine experimental · 2025Review
- Hemoadsorption in Children with Cytokine Storm Using the Jafron HA330 and HA380 Cartridges.Journal of clinical medicine · 2025Review
- Extracorporeal Cytokine Adsorption in Sepsis: Current Evidence and Future Perspectives.Biomedicines · 2025Review
- Reassessing sepsis research: new clues for old players and new players for an old symptom to improve patient outcomes.EXCLI journal · 2025Review
- Hemoadsorption in critically ill neonatal and pediatric patients: a retrospective cohort study from a Latin American tertiary center.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
While a dysregulated immune response is at the center of the sepsis definition, standard care is still solely focussed on prompt administration of antimicrobial therapy, source control, resuscitation and organ supportive therapies. Extracorporeal blood purification therapies, such as haemoadsorption, have been proposed as a possible adjunctive therapy to standard care in sepsis. These adsorption devices aim to rebalance the dysregulated immune response by removal of excessive amounts of circulating inflammatory mediators, including cytokines and endotoxins. Thus far, the effects of haemoadsorption on clinical outcomes have been insufficiently studied and although its routine use is not justified based on the current evidence, multiple centers use these devices in patients with severe septic shock. This narrative review describes the most well-studied adsorption devices as well as a novel selective adsorption device called the 'IL-6-Sieve', including in vitro data showing its capturing potential. Finally, it addresses important considerations for future trials on haemoadsorption in septic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.